IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, February 2024

Efficacy of Intrathecal Ziconotide in the Management of Several Chronic Pain - A Review

Kedar Mathpati[1], Gorkatte Vaishnavi[1], Kulkarni Aakanksha[1], Rushikesh Sarde[2], Sneha Vairagkar[3]
B.Pharm Students , Department of Pharmacology[1]
Assistant Professor, Department of Pharmaceutics[2,3]
Latur College of Pharmacy, Hasegaon Latur, Maharashtra, India

Abstract: *Ziconotide is a conopeptide intrathecal(IT) analgesic which is approved by the US Food and Drug Administration(FDA) for the operation of severe habitual pain. It's a synthetic fellow of a naturally being conopeptide set up in the venom of the fish- eating marine cone crawler and provides analgesia via binding to N- type voltage-sensitive calcium channels in the spinal cord.As ziconotide is a peptide, it's anticipated to be fully degraded by endopeptidases and exopeptidases(Phase I hydrolytic enzymes) extensively located throughout the body, and not by other Phase I biotransformation processes(including the cytochrome P450 system) or by Phase II conjugation responses.*

therefore, IT administration, low tube ziconotide attention, and metabolism by ubiquitous peptidases make metabolic relations of other medicines with ziconotide doubtful. Side goods of ziconotide which tend to do further generally at advanced boluses may include.

nausea, puking, confusion, postural hypotension, abnormal gait, urinary retention, nystagmus/ amblyopia, doziness/ doziness(reduced position of knowledge), dizziness or flightiness, weakness, visual problems(eg, double vision), elevation of serum creatine kinase, or vestibular side goods.

Firstly, when ziconotide was first administered In mortal subjects, the titration schedule was exorbitantly aggressive, performing in a large number of side goods effect. As a result, croakers realized that ziconotide's effectiveness was fairly limited. Treatment window. Several studies show that ziconotide is safe when used meetly Use effective intrathecal anesthetics alone or in combination with other intrathecal anesthetics.

Objective

The experience of habitual pain is one of the commonest reasons individualities seek medical attention, making the operation of habitual pain a major issue in clinical practice. medicine metabolism and responses are affected by numerous factors, with inheritable variations offering only a partial explanation of an existent's response. There's a deficit of substantiation for the benefits of pharmacogenetic testing in the environment of pain operation.

Summary: Pharmacological operation of severe habitual pain is delicate to achieve with presently available analgesic medicines, and remains a large unmet remedial need. The synthetic peptide ziconotide has been approved by the US Food and Drug Administration and the European Medicines Agency for intrathecal treatment of cases with severe habitual pain that's refractory to other treatment modalities. Ziconotide is the first member in the new medicine class of picky N- type voltage-sensitive calcium- channel blockers.

The ziconotide- convinced leaguer of N- type calcium channels in the spinal cord inhibits release of pain-applicable neurotransmitters from central outstations of primary sensational neurons. By this medium, ziconotide can effectively reduce pain. still, because ziconotide has a narrow remedial indicator due to its serious central nervous system side goods, ziconotide treatment is applicable only for a small number of cases with severe habitual pain. We give an overview of the benefits and limitations of intrathecal ziconotide treatment and consider implicit unborn developments for this new class of medicines.

Keywords: ziconotide, Prialt, analgesic medicine, N- type calcium channel blocker, severe habitual pain,

DOI: 10.48175/568

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, February 2024

REFERENCES

[1]. https//www.sciencedirect.com/science/article/abs/pii/S0140673610603546
[2]. https//www.sciencedirect.com/science/article/pii/S0009912014003890
[3]. https//www.sciencedirect.com/science/article/pii/S1094715921053939
[4]. https//www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/ziconotide
[5]. https//onlinelibrary.wiley.com/doi/full/10.1002/brb3.2055.
[6]. https//www.sciencedirect.com/science/article/pii/S088539240800376X
[7]. htthttps//www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/ziconotideps
[8]. https//www.researchgate.net/publication/256378140_Intrathecal_Ziconotide_A_Review_of_Its_Use_in_Patients_with_Chronic_Pain_Refractory_to_Other_Systemic_or_Intrathecal_Analgesics
[9]. https//meridian.allenpress.com/mhc/article/8/5/242/37271/Ziconotide-induced-psychosis-A-case-report-and
[10]. https//cyberleninka.org/article/n/656792.pdf
[11]. https//www.slideshare.net/rahul_chikki/chronic-pain-managment
[12]. https//www.ncbi.nlm.nih.gov/pmc/articles/PMC5801619/
[13]. https//www.sciencedirect.com/science/article/abs/pii/S0140673610603546
[14]. https//onlinelibrary.wiley.com/doi/full/10.1002/brb3.2055
[15]. https//www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/ziconotide